Current Approaches and Future Directions in the Treatment of Leprosy

Overview

Journal Res Rep Trop Med

Publisher Dove Medical Press

Specialty Infectious Diseases

Date 2018 Aug 14

PMID 30100775

Citations 9

Authors

Sophie M Worobec

Affiliations

Soon will be listed here.

Abstract

This review surveys current treatments and future treatment trends in leprosy from a clinical perspective. The World Health Organization provides a multidrug treatment regimen that targets the bacillus which causes leprosy. Several investigational drugs are available for the treatment of drug-resistant . Future directions in leprosy treatment will focus on: the molecular signaling mechanism uses to avoid triggering an immune response; prospective studies of the side effects experienced during multiple-drug therapy; recognition of relapse rates post-completion of designated treatments; combating multidrug resistance; vaccine development; development of new diagnostic tests; and the implications of the recent discovery of a genetically distinct leprosy-causing bacillus, .

Citing Articles

The Neurological Impact of Leprosy: Manifestations and Treatment Approaches.

Calderone A, Aloisi M, Casella C, Fiannacca S, Cosenza B, Quartarone A Neurol Int. 2024; 16(6):1492-1508.

PMID: 39585070 PMC: 11587477. DOI: 10.3390/neurolint16060111.

Mechanisms of Linezolid Resistance in Mycobacteria.

Gan W, Ng H, Ngeow Y Pharmaceuticals (Basel). 2023; 16(6).

PMID: 37375732 PMC: 10303974. DOI: 10.3390/ph16060784.

Global leprosy scenario: Eradication, elimination or control?.

Gupte M Indian J Med Res. 2023; 157(1):1-4.

PMID: 37040220 PMC: 10284364. DOI: 10.4103/ijmr.ijmr_2305_22.

Protective Efficacy of BCG Vaccine against and Non-Tuberculous Mycobacterial Infections.

Orujyan D, Narinyan W, Rangarajan S, Rangchaikul P, Prasad C, Saviola B Vaccines (Basel). 2022; 10(3).

PMID: 35335022 PMC: 8952781. DOI: 10.3390/vaccines10030390.

Natural-Product-Based Solutions for Tropical Infectious Diseases.

Adegboye O, Field M, Kupz A, Pai S, Sharma D, Smout M Clin Microbiol Rev. 2021; 34(4):e0034820.

PMID: 34494873 PMC: 8673330. DOI: 10.1128/CMR.00348-20.

References

Matsuoka M, Budiawan T, Aye K, Kyaw K, Tan E, Dela Cruz E . The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed leprosy patients from Myanmar, Indonesia and the Philippines. Lepr Rev. 2008; 78(4):343-52. View

Portaels F, Fissette K, De Ridder K, Macedo P, De Muynck A, Silva M . Effects of freezing and thawing on the viability and the ultrastructure of in vivo grown mycobacteria. Int J Lepr Other Mycobact Dis. 1988; 56(4):580-7. View

Robbins G, Tripathy V, Misra V, Mohanty R, Shinde V, Gray K . Ancient skeletal evidence for leprosy in India (2000 B.C.). PLoS One. 2009; 4(5):e5669. PMC: 2682583. DOI: 10.1371/journal.pone.0005669. View

Vera-Cabrera L, Escalante-Fuentes W, Gomez-Flores M, Ocampo-Candiani J, Busso P, Singh P . Case of diffuse lepromatous leprosy associated with "Mycobacterium lepromatosis". J Clin Microbiol. 2011; 49(12):4366-8. PMC: 3232982. DOI: 10.1128/JCM.05634-11. View

Moschella S . An update on the diagnosis and treatment of leprosy. J Am Acad Dermatol. 2004; 51(3):417-26. DOI: 10.1016/j.jaad.2003.11.072. View

Han X, Sizer K, Thompson E, Kabanja J, Li J, Hu P . Comparative sequence analysis of Mycobacterium leprae and the new leprosy-causing Mycobacterium lepromatosis. J Bacteriol. 2009; 191(19):6067-74. PMC: 2747882. DOI: 10.1128/JB.00762-09. View

Liu P, Wheelwright M, Teles R, Komisopoulou E, Edfeldt K, Ferguson B . MicroRNA-21 targets the vitamin D-dependent antimicrobial pathway in leprosy. Nat Med. 2012; 18(2):267-73. PMC: 3274599. DOI: 10.1038/nm.2584. View

Burgos J, de la Cruz E, Paredes R, Andaya C, Gelber R . The activity of several newer antimicrobials against logarithmically multiplying M. leprae in mice. Lepr Rev. 2011; 82(3):253-8. View

Faber W, Jensema A, Goldschmidt W . Treatment of recurrent erythema nodosum leprosum with infliximab. N Engl J Med. 2006; 355(7):739. DOI: 10.1056/NEJMc052955. View

10.

Duncan M, Melsom R, Pearson J, Menzel S, Barnetson R . A clinical and immunological study of four babies of mothers with lepromatous leprosy, two of whom developed leprosy in infancy. Int J Lepr Other Mycobact Dis. 1983; 51(1):7-17. View

11.

Jayalakshmi . Histopathology of skin lesions in leprosy. Malays J Pathol. 1980; 3:39-45. View

12.

Monot M, Honore N, Garnier T, Zidane N, Sherafi D, Paniz-Mondolfi A . Comparative genomic and phylogeographic analysis of Mycobacterium leprae. Nat Genet. 2009; 41(12):1282-9. DOI: 10.1038/ng.477. View

13.

Geluk A, Bobosha K, van der Ploeg-van Schip J, Spencer J, Banu S, Martins M . New biomarkers with relevance to leprosy diagnosis applicable in areas hyperendemic for leprosy. J Immunol. 2012; 188(10):4782-91. PMC: 3345093. DOI: 10.4049/jimmunol.1103452. View

14.

Ebenezer G, Suneetha S, Mohandas R, Arunthathi S . Multibacillary nerve histology in clinically diagnosed borderline tuberculoid leprosy patients. Int J Lepr Other Mycobact Dis. 1996; 64(3):311-5. View

15.

Rocha A, Cunha M, Diniz L, Salgado C, Aires M, Nery J . Drug and multidrug resistance among Mycobacterium leprae isolates from Brazilian relapsed leprosy patients. J Clin Microbiol. 2012; 50(6):1912-7. PMC: 3372169. DOI: 10.1128/JCM.06561-11. View

16.

. Global leprosy situation, 2010. Wkly Epidemiol Rec. 2010; 85(35):337-48. View

17.

Deps P, Nasser S, Guerra P, Simon M, Birshner R, Rodrigues L . Adverse effects from multi-drug therapy in leprosy: a Brazilian study. Lepr Rev. 2007; 78(3):216-22. View

18.

Desikan K, Sreevatsa . Extended studies on the viability of Mycobacterium leprae outside the human body. Lepr Rev. 1995; 66(4):287-95. View

19.

Williams D, Pittman T, Deshotel M, Oby-Robinson S, Smith I, Husson R . Molecular basis of the defective heat stress response in Mycobacterium leprae. J Bacteriol. 2007; 189(24):8818-27. PMC: 2168617. DOI: 10.1128/JB.00601-07. View

20.

Worobec S . Treatment of leprosy/Hansen's disease in the early 21st century. Dermatol Ther. 2009; 22(6):518-37. DOI: 10.1111/j.1529-8019.2009.01274.x. View